Logo image of CGEN

COMPUGEN LTD (CGEN) Stock Fundamental Analysis

NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD

1.65  +0.01 (+0.61%)

After market: 1.64 -0.01 (-0.61%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CGEN. CGEN was compared to 557 industry peers in the Biotechnology industry. CGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CGEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CGEN has reported negative net income.
In the past year CGEN had a positive cash flow from operations.
In the past 5 years CGEN always reported negative net income.
CGEN had negative operating cash flow in 4 of the past 5 years.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of CGEN (-12.38%) is better than 82.94% of its industry peers.
The Return On Equity of CGEN (-25.92%) is better than 80.97% of its industry peers.
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROIC N/A
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CGEN's Gross Margin of 71.54% is amongst the best of the industry. CGEN outperforms 82.59% of its industry peers.
CGEN's Gross Margin has declined in the last couple of years.
CGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
CGEN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CGEN has an Altman-Z score of -3.77. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CGEN (-3.77) is comparable to the rest of the industry.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -3.77
ROIC/WACCN/A
WACC9.02%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CGEN has a Current Ratio of 5.26. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN has a Current ratio (5.26) which is comparable to the rest of the industry.
A Quick Ratio of 5.26 indicates that CGEN has no problem at all paying its short term obligations.
The Quick ratio of CGEN (5.26) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.26
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

CGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.79%, which is quite good.
Looking at the last year, CGEN shows a very negative growth in Revenue. The Revenue has decreased by -23.40% in the last year.
The Revenue has been growing by 66.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-23.4%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.75%

3.2 Future

The Earnings Per Share is expected to decrease by -13.08% on average over the next years. This is quite bad
The Revenue is expected to decrease by -1.06% on average over the next years.
EPS Next Y25.62%
EPS Next 2Y13.96%
EPS Next 3Y15.29%
EPS Next 5Y-13.08%
Revenue Next Year-66.37%
Revenue Next 2Y-4.04%
Revenue Next 3Y2.48%
Revenue Next 5Y-1.06%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGEN. In the last year negative earnings were reported.
Also next year CGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CGEN is valued cheaply inside the industry as 99.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.99
EV/EBITDA N/A
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

CGEN's earnings are expected to grow with 15.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.96%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

CGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (6/16/2025, 8:00:00 PM)

After market: 1.64 -0.01 (-0.61%)

1.65

+0.01 (+0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners18.11%
Inst Owner Change23.68%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap147.74M
Analysts88
Price Target6.12 (270.91%)
Short Float %1.76%
Short Ratio6.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-142.14%
Min EPS beat(2)-193.59%
Max EPS beat(2)-90.69%
EPS beat(4)1
Avg EPS beat(4)-117.3%
Min EPS beat(4)-256.51%
Max EPS beat(4)71.58%
EPS beat(8)3
Avg EPS beat(8)-64.31%
EPS beat(12)6
Avg EPS beat(12)-35.62%
EPS beat(16)10
Avg EPS beat(16)-21.03%
Revenue beat(2)0
Avg Revenue beat(2)-48.85%
Min Revenue beat(2)-91.73%
Max Revenue beat(2)-5.97%
Revenue beat(4)1
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-91.73%
Max Revenue beat(4)163.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.32%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)0%
EPS NY rev (3m)2.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.92%
Revenue NY rev (1m)-51.52%
Revenue NY rev (3m)-55.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.3
P/FCF 2.99
P/OCF 2.98
P/B 2.69
P/tB 2.69
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.55
FCFY33.5%
OCF(TTM)0.55
OCFY33.57%
SpS0.31
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.54%
FCFM 177.6%
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 24.28%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.26
Altman-Z -3.77
F-Score5
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)54.17%
Cap/Depr(5y)49.83%
Cap/Sales(3y)2.49%
Cap/Sales(5y)4.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y25.62%
EPS Next 2Y13.96%
EPS Next 3Y15.29%
EPS Next 5Y-13.08%
Revenue 1Y (TTM)-23.4%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.75%
Revenue Next Year-66.37%
Revenue Next 2Y-4.04%
Revenue Next 3Y2.48%
Revenue Next 5Y-1.06%
EBIT growth 1Y-14.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.23%
OCF growth 3YN/A
OCF growth 5YN/A